January 20, 2025 — MediLink Therapeutics (“MediLink”), a clinical-stage biotechnology company, announced that the Center for Drug Evaluation (CDE) granted Breakthrough Therapy Designation to YL201, for the treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC). Previously, the Breakthrough Therapy Designation was also granted for YL201 by the CDE for the treatment of recurrent small cell lung cancer.
2025-01-20
Suzhou, China, Jan 14, 2025 -- MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, announced that a clinical collaboration has been established with AstraZeneca to explore the therapeutic potential in solid tumors, of the combination of MediLink's B7-H3-targeting antibody-drug conjugate (ADC) YL201 and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® ( durvalumab).
2025-01-14
SUZHOU, SHANGHAI and CAMBRIDGE, Mass., Jan 10, 2025 -- MediLink Therapeutics (Suzhou) Co., Ltd. (“MediLink”) today announced a new strategic collaboration and worldwide license agreement with Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) to use MediLink’s TMALIN® antibody-drug conjugate (ADC) platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab.
2025-01-10
